Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.47	$4.44	$3.00 ▼ $25.45	$216.17M	0.3	1.73 million shs	N/A
MNPR Monopar Therapeutics	$31.84 -3.5%	$37.96	$2.25 ▼ $54.30	$203.61M	1.05	24,629 shs	53,000 shs
PDSB PDS Biotechnology	$1.15 -1.7%	$1.29	$0.85 ▼ $4.29	$54.56M	0.95	328,634 shs	135,494 shs
PRQR ProQR Therapeutics	$2.21 +3.3%	$2.13	$1.07 ▼ $4.62	$225.15M	0.43	284,864 shs	234,775 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	-1.11%	+0.22%	-1.11%	+9.02%	-73.94%
MNPR Monopar Therapeutics	-1.52%	-1.52%	-28.93%	-6.88%	+1,230.65%
PDSB PDS Biotechnology	0.00%	+0.86%	+1.74%	-25.48%	-66.14%
PRQR ProQR Therapeutics	+5.42%	+5.94%	-8.55%	+26.63%	+1.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.0468 of 5 stars	2.9	0.0	1.8	1.7	1.3
MNPR Monopar Therapeutics	2.8508 of 5 stars	3.4	4.0	2.5	2.5	0.0
PDSB PDS Biotechnology	2.1485 of 5 stars	3.5	3.0	3.2	0.0	0.0
PRQR ProQR Therapeutics	2.6266 of 5 stars	3.6	5.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	244.52% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	88.44% Upside
PDSB PDS Biotechnology	3.00	Buy	$10.00	769.57% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	261.99% Upside

Current Analyst Ratings Breakdown

Latest PDSB, MNPR, CRGX, and PRQR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/1/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$8.46 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.34 per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.36	N/A	N/A	$0.72 per share	3.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	N/A
PDSB PDS Biotechnology	-$37.61M	-$0.92	N/A	N/A	N/A	N/A	-184.56%	-79.00%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)

Latest PDSB, MNPR, CRGX, and PRQR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PDSB PDS Biotechnology	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	12.37	12.37
MNPR Monopar Therapeutics	N/A	33.93	33.93
PDSB PDS Biotechnology	0.81	2.92	2.92
PRQR ProQR Therapeutics	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
MNPR Monopar Therapeutics	1.83%
PDSB PDS Biotechnology	26.84%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
MNPR Monopar Therapeutics	20.50%
PDSB PDS Biotechnology	9.20%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable
PDSB PDS Biotechnology	20	46.63 million	42.34 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

PDSB, MNPR, CRGX, and PRQR Headlines

Recent News About These Companies

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

August 20 at 2:37 AM | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts

August 19 at 2:39 AM | americanbankingnews.com

PRQR | ProQR Therapeutics N.V. Stock Price & News - WSJ

August 12, 2025 | wsj.com

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital

August 9, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 8, 2025 | marketbeat.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 7, 2025 | globenewswire.com

ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Monaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

July 30, 2025 | marketbeat.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB, MNPR, CRGX, and PRQR Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.47 0.00 (0.00%)

As of 08/19/2025

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Monopar Therapeutics NASDAQ:MNPR

$31.84 -1.16 (-3.52%)

Closing price 04:00 PM Eastern

Extended Trading

$31.76 -0.07 (-0.24%)

As of 04:20 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

PDS Biotechnology NASDAQ:PDSB

$1.15 -0.02 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.04%)

As of 07:43 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

ProQR Therapeutics NASDAQ:PRQR

$2.21 +0.07 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 -0.03 (-1.36%)

As of 06:30 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time